Published in Transplantation on June 15, 2005
Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells (2009) 2.57
Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol (2009) 1.88
Early chimerism threshold predicts sustained engraftment and NK-cell tolerance in prenatal allogeneic chimeras. Blood (2008) 1.73
Stem cells in the umbilical cord. Stem Cell Rev (2006) 1.63
Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. BMC Cell Biol (2010) 1.62
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. J Biol Chem (2008) 1.56
Hematopoietic stem cell mobilization: updated conceptual renditions. Leukemia (2012) 1.49
Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem (2009) 1.47
Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol (2012) 1.45
Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther (2007) 1.35
Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy (2009) 1.35
Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther (2011) 1.28
Mesenchymal stem cells: Molecular characteristics and clinical applications. World J Stem Cells (2010) 1.27
Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag (2010) 1.21
Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev (2010) 1.18
Clinical applications of mesenchymal stem cells. Korean J Intern Med (2013) 1.18
Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev (Orlando) (2008) 1.17
Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton. J Cell Biochem (2010) 1.16
Therapeutic potential of mesenchymal stem cells in regenerative medicine. Stem Cells Int (2013) 1.14
Cell sources for bone tissue engineering: insights from basic science. Tissue Eng Part B Rev (2011) 1.10
Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med (2013) 1.08
Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin Biol Ther (2010) 1.07
Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues. J R Soc Interface (2010) 1.06
Bone regeneration: stem cell therapies and clinical studies in orthopaedics and traumatology. J Cell Mol Med (2011) 1.03
ES, iPS, MSC, and AFS cells. Stem cells exploitation for Pediatric Surgery: current research and perspective. Pediatr Surg Int (2009) 1.02
Cellular treatments for spinal cord injury: the time is right for clinical trials. Neurotherapeutics (2011) 1.01
Stem cells in the trabecular meshwork: present and future promises. Exp Eye Res (2008) 1.00
Comprehensive characterization of mesenchymal stem cells from human placenta and fetal membrane and their response to osteoactivin stimulation. Stem Cells Int (2012) 0.99
Upregulating CXCR4 in human fetal mesenchymal stem cells enhances engraftment and bone mechanics in a mouse model of osteogenesis imperfecta. Stem Cells Transl Med (2011) 0.99
The effects of culture on genomic imprinting profiles in human embryonic and fetal mesenchymal stem cells. Epigenetics (2011) 0.98
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics. Stem Cells Int (2013) 0.98
HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother (2009) 0.96
Stem cell differentiation and expansion for clinical applications of tissue engineering. J Cell Mol Med (2007) 0.96
Epigenetic regulation of mesenchymal stem cells: a focus on osteogenic and adipogenic differentiation. Stem Cells Int (2011) 0.96
Potential implications of cell therapy for osteogenesis imperfecta. Int J Clin Rheumtol (2009) 0.95
Therapeutic application of mesenchymal stem cells in bone and joint diseases. Clin Exp Med (2012) 0.93
Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells. PLoS One (2013) 0.92
Fate of amnion-derived stem cells transplanted to the fetal rat brain: migration, survival and differentiation. J Cell Mol Med (2008) 0.92
Ontological differences in first compared to third trimester human fetal placental chorionic stem cells. PLoS One (2012) 0.91
Mesenchymal Progenitor Cells and Their Orthopedic Applications: Forging a Path towards Clinical Trials. Stem Cells Int (2010) 0.91
Bone regeneration: the stem/progenitor cells point of view. J Cell Mol Med (2009) 0.90
Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned? Stem Cell Res Ther (2014) 0.90
Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy. Oxid Med Cell Longev (2015) 0.90
Bone regeneration with mesenchymal stem cells. Clin Cases Miner Bone Metab (2012) 0.88
Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child (2006) 0.86
Immune response to stem cells and strategies to induce tolerance. Philos Trans R Soc Lond B Biol Sci (2007) 0.86
Application of stem cells in bone repair. Skeletal Radiol (2008) 0.85
Fetal liver-derived mesenchymal stem cell engraftment after allogeneic in utero transplantation into rabbits. Stem Cells Dev (2011) 0.85
A xenogeneic-free protocol for isolation and expansion of human adipose stem cells for clinical uses. PLoS One (2013) 0.85
Local transplantation is an effective method for cell delivery in the osteogenesis imperfecta murine model. Int Orthop (2014) 0.84
Reconciling the effects of inflammatory cytokines on mesenchymal cell osteogenic differentiation. J Surg Res (2013) 0.84
Microchimerism in endocrine pathology. Endocr Pathol (2009) 0.83
Mesenchymal stem cells (MSCs) as skeletal therapeutics-an update. J Biomed Sci (2016) 0.81
Stem cell therapy for voiding and erectile dysfunction. Nat Rev Urol (2012) 0.81
Interferon gamma and T cells inhibit osteogenesis induced by allogeneic mesenchymal stromal cells. J Orthop Res (2012) 0.81
Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta. Front Pharmacol (2014) 0.80
Human embryonic stem cell-derived mesenchymal stromal cells. Transfusion (2011) 0.80
Recent developments in osteogenesis imperfecta. F1000Res (2015) 0.80
Mesenchymal Stromal Cells Affect Disease Outcomes via Macrophage Polarization. Stem Cells Int (2015) 0.80
Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta. Stem Cells Dev (2013) 0.79
Developmental definition of MSCs: new insights into pending questions. Cell Reprogram (2011) 0.79
In utero therapy for congenital disorders using amniotic fluid stem cells. Front Pharmacol (2014) 0.79
A new platelet cryoprecipitate glue promoting bone formation after ectopic mesenchymal stromal cell-loaded biomaterial implantation in nude mice. Stem Cell Res Ther (2013) 0.79
Induced pluripotent stem (iPS) cells from human fetal stem cells (hFSCs). Organogenesis (2013) 0.78
Eliminating the need of serum testing using low serum culture conditions for human bone marrow-derived mesenchymal stromal cell expansion. Biomed Eng Online (2013) 0.77
Rationale for the potential use of mesenchymal stromal cells in liver transplantation. World J Gastroenterol (2014) 0.77
Stem cells for the treatment of musculoskeletal pain. World J Stem Cells (2015) 0.77
Cellular therapy for repair of cardiac damage after acute myocardial infarction. Int J Cell Biol (2009) 0.77
Mesenchymal stem cell-derived microparticles: a promising therapeutic strategy. Int J Mol Sci (2014) 0.77
Allele dependent silencing of collagen type I using small interfering RNAs targeting 3'UTR Indels - a novel therapeutic approach in osteogenesis imperfecta. Int J Med Sci (2013) 0.76
Human bone marrow-derived mesenchymal stem cells. Libyan J Med (2007) 0.76
Intrauterine Bone Marrow Transplantation in Osteogenesis Imperfecta Mice Yields Donor Osteoclasts and Osteomacs but Not Osteoblasts. Stem Cell Reports (2015) 0.76
In vivo tracking of human placenta derived mesenchymal stem cells in nude mice via ¹⁴C-TdR labeling. BMC Biotechnol (2015) 0.76
Bone repair with skeletal stem cells: rationale, progress to date and clinical application. Ther Adv Musculoskelet Dis (2016) 0.76
Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS). Placenta (2011) 0.76
Boosting Hematopoietic Engraftment after in Utero Transplantation through Vascular Niche Manipulation. Stem Cell Reports (2016) 0.75
Applications of regenerative medicine in organ transplantation. J Pharm Bioallied Sci (2015) 0.75
Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model. Cytotherapy (2014) 0.75
Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta. Eur J Hum Genet (2013) 0.75
Prospects and limitations of improving skeletal growth in a mouse model of spondyloepiphyseal dysplasia caused by R992C (p.R1192C) substitution in collagen II. PLoS One (2017) 0.75
Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease. World J Gastroenterol (2016) 0.75
Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation. Tissue Eng Part B Rev (2014) 0.75
Characterization of Fetal Tissue-derived Mesenchymal Stem Cells. Int J Stem Cells (2009) 0.75
In Utero Stem Cell Transplantation: Potential Therapeutic Application for Muscle Diseases. Stem Cells Int (2017) 0.75
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 11.77
Dynamics of fat cell turnover in humans. Nature (2008) 9.80
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol (2003) 5.35
Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med (2011) 4.09
One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA (2009) 3.29
Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics (2003) 2.85
Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation (2003) 2.49
Male gender predisposes to prolongation of pregnancy. Am J Obstet Gynecol (2002) 2.23
EXPRESS study shows significant regional differences in 1-year outcome of extremely preterm infants in Sweden. Acta Paediatr (2013) 2.19
PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet (2009) 2.16
Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res (2005) 2.16
Age-dependent cognitive changes in carriers of the fragile X syndrome. Cortex (2007) 2.10
[Suggestion to the Swedish Medical Association: Provide support for those accused of medical errors]. Lakartidningen (2015) 1.98
The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood (2007) 1.96
Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 1.93
Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant (2011) 1.90
Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulin-like growth factor-1 deficit. Pediatrics (2006) 1.85
No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica (2007) 1.82
A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation (2004) 1.75
Prenatal ultrasound scanning and the risk of schizophrenia and other psychoses. Epidemiology (2007) 1.71
One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant (2010) 1.69
Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res (2004) 1.65
Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol (2008) 1.63
Defining the risks of mesenchymal stromal cell therapy. Cytotherapy (2010) 1.60
Functional studies of mesenchymal stem cells derived from adult human adipose tissue. Exp Cell Res (2005) 1.57
Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood (2002) 1.55
Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant (2011) 1.54
Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leuk Lymphoma (2008) 1.53
Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology (2006) 1.53
A genetic study of Wilson's disease in the United Kingdom. Brain (2013) 1.53
Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica (2006) 1.52
Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol (2004) 1.52
Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. Hepatology (2015) 1.49
Nephrin TRAP mice lack slit diaphragms and show fibrotic glomeruli and cystic tubular lesions. J Am Soc Nephrol (2002) 1.48
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood (2004) 1.47
Neurodevelopmental outcome in extremely preterm infants at 2.5 years after active perinatal care in Sweden. JAMA (2013) 1.47
Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol (2012) 1.46
Postpartum ultrasound in women with postpartum endometritis, after cesarean section and after manual evacuation of the placenta. Acta Obstet Gynecol Scand (2007) 1.45
Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol (2006) 1.44
Haemochromatosis-associated HFE genotypes in English blood donors: age-related frequency and biochemical expression. J Hepatol (2003) 1.44
Genetic testing in the assessment of living related kidney donors at risk of autosomal dominant polycystic kidney disease. Transplantation (2015) 1.44
First trimester ultrasound scans and left-handedness. Epidemiology (2002) 1.43
Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation (2004) 1.43
Litmus tests for verification of feeding tube location in infants: evaluation of their clinical use. J Clin Nurs (2005) 1.42
[Prenatal screening for chromosome abnormalities--time to change strategy]. Lakartidningen (2006) 1.40
Experiences with fetomaternal alloimmune thrombocytopenia at a Swedish hospital over a 10-year period. Acta Obstet Gynecol Scand (2003) 1.39
The emerging fragile X premutation phenotype: evidence from the domain of social cognition. Brain Cogn (2005) 1.38
Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells (2012) 1.36
Transgenic mice with pancellular enhanced green fluorescent protein expression in primitive hematopoietic cells and all blood cell progeny. Genesis (2005) 1.35
Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol (2008) 1.34
Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci (2003) 1.34
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood (2010) 1.33
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci (2005) 1.30
Human cytomegalovirus inhibits neuronal differentiation and induces apoptosis in human neural precursor cells. J Virol (2006) 1.30
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant (2011) 1.29
On the origin of trisomy 21 Down syndrome. Mol Cytogenet (2008) 1.29
Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol (2007) 1.28
Trustful bonds: a key to "becoming a mother" and to reciprocal breastfeeding. Stories of mothers of very preterm infants at a neonatal unit. Soc Sci Med (2005) 1.28
Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res (2005) 1.25
Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood (2008) 1.23
Unexplained fractures in infancy: looking for fragile bones. Arch Dis Child (2007) 1.22
Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with osteogenesis imperfecta type I-IV. Hum Mutat (2006) 1.22
Lung epithelial cells and type II pneumocytes of donor origin after allogeneic hematopoietic stem cell transplantation. Transplantation (2004) 1.21
Postnatal peer counselling on exclusive breastfeeding of low-birthweight infants: a randomized, controlled trial. Acta Paediatr (2005) 1.21
Maternal microchimerism in human fetal tissues. Am J Obstet Gynecol (2008) 1.20
Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood (2004) 1.20
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. Biol Blood Marrow Transplant (2009) 1.19
Late human cytomegalovirus (HCMV) proteins inhibit differentiation of human neural precursor cells into astrocytes. J Neurosci Res (2007) 1.17
New pedigrees and novel mutation expand the phenotype of REEP1-associated hereditary spastic paraplegia (HSP). Neurogenetics (2008) 1.17
Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant (2009) 1.15
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica (2011) 1.15
Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2008) 1.15
Implementing knowledge into practice for improved neonatal survival; a cluster-randomised, community-based trial in Quang Ninh province, Vietnam. BMC Health Serv Res (2011) 1.15
Effect of Facilitation of Local Maternal-and-Newborn Stakeholder Groups on Neonatal Mortality: Cluster-Randomized Controlled Trial. PLoS Med (2013) 1.14
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy (2009) 1.14
Effects of socioeconomic status on breastfeeding duration in mothers of preterm and term infants. Eur J Public Health (2007) 1.14
Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open (2013) 1.14
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood (2005) 1.14
Causes of neonatal death: results from NeoKIP community-based trial in Quang Ninh province, Vietnam. Acta Paediatr (2011) 1.14
Unreported births and deaths, a severe obstacle for improved neonatal survival in low-income countries; a population based study. BMC Int Health Hum Rights (2008) 1.14
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood (2010) 1.14
Lactobacillus rhamnosus GG decreases lipopolysaccharide-induced systemic inflammation in a gastrostomy-fed infant rat model. J Pediatr Gastroenterol Nutr (2006) 1.12
Sustainability in changing clinical practice promotes evidence-based nursing care. J Adv Nurs (2003) 1.12
Understanding work contextual factors: a short-cut to evidence-based practice? Worldviews Evid Based Nurs (2006) 1.12
Characterization of cells in the developing human liver. Differentiation (2005) 1.11
KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol Immunol (2005) 1.10
Implementing a simplified neonatal resuscitation protocol-helping babies breathe at birth (HBB) - at a tertiary level hospital in Nepal for an increased perinatal survival. BMC Pediatr (2012) 1.09